<DOC>
	<DOCNO>NCT01256060</DOCNO>
	<brief_summary>Extensive data accumulate suggest central release oxytocin important social cognition function , well likely involved anxiety modulation repetitive behavior . The principal investigator study previously document : 1 ) association Autism Spectrum Disorder single nuclear polymorphism oxytocin receptor gene , 2 ) ability measure oxytocin level blood enzyme immunoassay 3 ) preliminary data support safety efficacy intranasal oxytocin treatment social deficit repetitive behavior adult autism . A medication treatment target core deficit Autism Spectrum Disorder childhood highly valuable could influence developmental trajectory make psychosocial intervention possible . In context , propose small dose find study confirm dose use adult study maximum tolerate dose youth . `</brief_summary>
	<brief_title>Intranasal Oxytocin Treatment Children Adolescents With ASD ( OXY )</brief_title>
	<detailed_description />
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>1 . Male female outpatient 1017 year age inclusive . 2 . Meet Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision criterion Autistic Disorder Asperger 's Disorder establish clinician support Autism Diagnostic Observation Schedule Autism Diagnostic Interview Revised . 3 . Have Clinician 's Global ImpressionSeverity score â‰¥ 4 ( moderately ill ) Baseline . 4 . Verbal Intelligent Quotient &gt; /= 70 . 5 . If already receive stable pharmacological nonpharmacologic educational , behavioral , and/or dietary intervention , continuous participation precede 3 month prior Screening electively initiate new modify ongoing intervention duration study . 6 . Have normal physical examination laboratory test result Screening . If abnormal , find ( ) must deem clinically insignificant Investigator . 7 . The participant caregiver must able speak understand English sufficiently allow completion study assessment . 1 . Patients born prior 35 week gestational age . 2 . Patients primary psychiatric diagnosis autism Screening . 3 . Patients current neurological disease , include , limited , epilepsy/seizure disorder ( except simple febrile seizure ) , movement disorder , tuberous sclerosis , fragile X , know genetic syndrome , know abnormal MRI/structural lesion brain . 4 . Pregnant female patient , sexually active female patient hormonal birth control sexually active female use two type nonhormonal birth control 5 . Patients medical condition might interfere conduct study , confound interpretation study result , endanger wellbeing . Patients evidence history malignancy significant hematological , endocrine , cardiovascular ( include rhythm disorder ) , respiratory , renal , hepatic , gastrointestinal disease . 6 . Patients sensitive Syntocinon component formulation 7 . Patients one following : HIV , Hepatitis B virus , Hepatitis C virus , hemophilia ( bleed problem , recent nose brain injury ) , abnormal blood pressure ( hypotension hypertension ) , drug abuse , immunity disorder severe depression . 8 . Patients unable tolerate venipuncture procedure blood sample .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Autism Spectrum disorder</keyword>
	<keyword>Oxytocin</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Children</keyword>
	<keyword>Pharmacology</keyword>
</DOC>